LXEO: Pivotal and phase I gene therapy programs advance toward major data and regulatory milestones by 2027
Lead programs in Friedreich's ataxia and PKP2 cardiomyopathy show strong efficacy signals, with pivotal and phase I studies progressing toward key readouts in 2026—2027. Streamlined CMC and commercial strategies target heart failure specialists, supported by a solid cash runway into 2028.Based on L…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.